I Fernando - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

I Fernando

Showing results (71-80 of 72) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 72 results.

Oncotarget|May 19, 2016

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cellsCaroline Jochems, Massimo Fantini, Romaine I Fernando, et al.

British Journal of Cancer|October 11, 2012

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.

Pageof 8

Search research articles

Showing results (71-80 of 72) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 72 results.

Oncotarget|May 19, 2016

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cellsCaroline Jochems, Massimo Fantini, Romaine I Fernando, et al.

British Journal of Cancer|October 11, 2012

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.

Pageof 8